

**PATENT**  
**P-9565-US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:	SIEGEL, S.J.	Examiner:	FUBARA B.M.
<u>Serial No.:</u>	10/046,504	Group Art Unit:	1618
Filed:	October 19, 2001	Confirmation No.	3358
Title:	POLYMER-BASED SURGICALLY IMPLATABLE HALOPERIDOL DELIVERY SYSTEMS AND METHODS FOR THEIR PRODUCTION AND USE		

**DECLARATION UNDER RULE 37 C.F.R. 1.132**

Assistant Commissioner for Patents  
Washington, DC 20231

I, SIEGEL, Steven, a citizen of United States of America, residing at 86 Highpoint Drive, Berwyn, PA 19312 and a named inventor of the present Application, hereby declare:

1. I am an Associate Professor at the University of Pennsylvania and Director of the Translational Neuroscience Program. I have an M.D. and a Ph.D. in Biomedical Science/Neurobiology from Mount Sinai School of Medicine. My fields of expertise are the Neurobiology and Pharmacology of Schizophrenia, The Clinical management of Psychotic Disorders, Electrophysiology, and Polymer based Drug Delivery. Specifically I have been involved in the study of Clinical studies of the Biological basis of Schizophrenia, Electrophysiological evaluation of candidate genes and neural pathways responsible for the abnormal behaviors and mental processes in schizophrenia,

the acute and lasting consequences of drugs of abuse including ketamine and nicotine, and discovery and development of long term biodegradable polymer drug delivery systems for schizophrenia and other neuropsychiatric disorders.

2. My Curriculum Vitae and list of publications are attached herewith as Appendix 1.
3. I have read the subject Application and have reviewed the patent prosecution history of the subject Application, including all the Office Actions and the references that served as basis for the Examiner's rejection alleging *inter-alia*, that a surgically implantable drug delivery system comprising a biodegradable polymer or copolymer selected from the group consisting of polylactide and lactide-co-glycolide copolymer and 20 to 40% haloperidol is obvious in view of the cited references.
4. Claim 1 of the subject Application recites a surgically implantable drug delivery system, comprising:
  - (a) a biodegradable polymer or copolymer, wherein said biodegradable polymer or copolymer consists essentially of polylactide or lactide-co-glycolide copolymer; and
  - (b) between about 20 to 40% haloperidol fabricated into an individual, surgically implantable implant via solvent casting and compression molding at a temperature and pressure which allows the haloperidol-polymer material to flow into a mold for the individual, surgically implantable implant which is surgically implanted underneath the skin of a patient, delivers steady state concentrations of haloperidol to the patient for 5 months or more and is removable from the patient in the event the patient exhibits unwanted side effects following implantation
5. Claim 4 of the subject application recites a method of producing an individual, surgically implantable implant which is surgically implanted underneath the skin of a patient for delivery of steady state concentrations of haloperidol to the patient for 5 months or more comprising:

- (a) dissolving between about 20% and 40% haloperidol and a biodegradable polymer consisting essentially of polylactide or lactide-co-glycolide copolymer in acetone;
  - (b) solvent casting the haloperidol and biodegradable polymer solution to produce a completely dry haloperidol-polymer material; and
  - (c) molding under compression the dry haloperidol-polymer material at a temperature and pressure which allows the haloperidol-polymer material to flow into a mold for the individual, surgically implantable implant which is surgically implanted underneath the skin of a patient, delivers steady state concentrations of haloperidol to the patient for 5 months or more, and is removable following implantation into a patient in the event the patient exhibits unwanted side effects following implantation.
6. The resulting biodegradable implant has a two stage pseudo zero-order release of 20-40% haloperidol into the blood of a patient over a period of about 5 months and is capable of being removed immediately upon the observation and determination of the need to do so due to undesirable side effects.
7. In the Office Action dated January 16, 2008 and the Final Office Action dated September 3, 2008; the Examiner rejected claims 1 and 3 under 35 U.S.C. § 103(a), as being unpatentable over Cheng et al, "A poly(D,L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol," in Journal of Controlled Release 55 (1998) 203-212. The Examiner alleged that Cheng et al., which describes haloperidol-loaded biodegradable poly(D,L-lactide-co-glycolide) (PLG) microsphere (abstract), achieved a 10% haloperidol. Further, the Examiner alleges that the "Surgically implantable drug delivery" is in the preamble and represents the intended use of the delivery system while the body of the claim fully defines the claimed system. The Examiner maintains that Cheng et al., discloses a drug content of from 14.6 to 23.9%, which can allegedly be loaded onto the PLG microspheres and therefore, taking the teaching of Cheng et al., one of ordinary skill in the art at the time the invention was made would have

reasonable expectation of success to formulate haloperidol loaded biodegradable poly(D,L-lactide-co-glycolide) (PLG) microsphere in which the drug load is 10% or from 14.6 to 23.9%.

8. The Examiner is incorrect in her assertions it would not have been obvious for a person skilled in the art to obtain Applicants' claimed invention based on Cheng et al. for the reasons set forth hereinafter.
9. The Haloperidol/Polymer system disclosed by Cheng et al., cannot achieve the 20-40% Haloperidol concentrations obtained in the implants of the subject application, since the polymer matrix and encapsulated drug form a unique physico-chemical combination with a characteristic release profile. As shown in Figure 5 of Cheng et al., at higher initial loading of the API, release rate is accelerated, unlike the results described in the present application showing a decrease in release rate with increasing actual initial loading, thereby teaching away from the subject Application. Increased drug flux with increased initial loading is expected (See e.g. Menemse Gümüşderelioglu and Günday Deniz, Journal of Biomaterials Science, Polymer Edition Volume 11, Number 10 / December, 2000, Pages 1039-1050 "Sustained release of mitomycin-C from poly(DL-lactide)/poly(DL-lactide-co-glycolide) films" showing that both the rate and the percentage of released MMC increased as the drug load increased from 0.5 to 2 mg MMC per 300 mg of polymer. See also, Sharma, Kuldeepak, 1987 "Mechanisms of Drug Diffusion from Polymeric Devices" Dissertation Abstracts International, Volume: 48-02, Section: B, page: 486, showing that initial drug load, drug loading solvents and the drug polymer interactions affect release of several drugs from devices comprising both hydrophilic and hydrophobic polymers studied showed an increase in release as the initial drug load increased.). In the subject Application, unexpectedly at high Haloperidol concentrations, matrix degradation changes and release rates are affected. As stated in the application on page 3, para. 26, higher Haloperidol loading concentration stabilizes the system, slowing the release rate. This shows in my opinion, that the polymer matrix used by Cheng et al., is substantially different than the polymer matrix used

in the present Application. Likewise any person of ordinary skill in the art, knowing about the effect of the polymer matrix on the encapsulated drug release would not expect the unexpected results in the present Application based on the results disclosed in Cheng et al.

10. **Due to known unique encapsulant/matrix interactions, a person skilled in the art would not draw any conclusions from the encapsulation efficiency of one encapsulant to another in the same polymer matrix.** In my opinion, Cheng et al. does not disclose a surgically implantable drug delivery system comprising a biodegradable polymer or copolymer selected from the group consisting of polylactide and lactide-co-glycolide copolymer and 20 to 40% haloperidol, nor is the disclosure credible considering the unexpected nature of the effects of higher Haloperidol loading on the release rate. Therefore, at the time the invention was made, the results described by Cheng et al. could not have made it obvious for a skilled practitioner that an actual 20-40% loading of Haloperidol in a polylactide or lactide-co-glycolide copolymer, as claimed in the subject Application would give the same or similar loading as 14.6-23.9% of 5-fluorouracyl in a PLG matrix.

The undersigned further declares that all statements made herein of his own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 2/27/9

  
Signature

UNIVERSITY OF PENNSYLVANIA - SCHOOL OF MEDICINE  
Curriculum Vitae

Updated: July 21, 2008

Steven J. Siegel, M.D., Ph.D.

Office Address: Translational Research Laboratories, Rm. 2223  
125 S. 31st Street  
Philadelphia PA 19104

Education:

1982-1986	B.A. - Colgate University	Neuroscience
1990 - 1994	Ph.D. - Mount Sinai School of Medicine	Neurobiology
1988 - 1996	M.D. - Medicine Mount Sinai School of Medicine	Medicine

Postgraduate Training and Fellowship Appointments:

1993	John D. & Catherine T. Training Fellowship, Mount Sinai School of Medicine
1994	Charles A. Dana Postdoctoral Fellowship, Mount Sinai School of Medicine
1996-2000	Wistar Scholar and Resident in Psychiatry, University of Pennsylvania
1999-2001	Postdoctoral Fellowship, Neuropsychiatry, Department of Psychiatry, University of Pennsylvania School of Medicine

Military Service:

None

Faculty Appointments:

2001 - 2008	Assistant Professor of Psychiatry, Department of Psychiatry, University of Pennsylvania School of Medicine
2008 - present	Associate Professor of Psychiatry with Tenure, Department of Psychiatry, University of Pennsylvania School of Medicine Director, Clinical Neuroscience Track, School of Medicine
2009 - present	Director, Division of Translational Neuroscience

Hospital and Administrative Appointments:

2001 - Present	- Attending Physician, Department of Psychiatry, Hospital of the University of Pennsylvania
2001 - Present	- Attending Physician, Department of Psychiatry, Presbyterian Medical Center
2007 - Present	- Attending Physician, Department of Psychiatry, Pennsylvania Hospital

Other Appointments:

2005 - Present	- Member, Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine
2006 - Present	- Member, Abramson Cancer Center

- 2005 – Present: Faculty member, Neuroscience Graduate Group, University of Pennsylvania  
– Supervising one Neuroscience Graduate Group PhD rotation student presently.  
School of Medicine
- 2005 – Present: Faculty member, Pharmacology Graduate Group, University of Pennsylvania  
School of Medicine – Supervising one Pharmacology Graduate Group PhD student  
and one PhD rotation student presently.
- 2008 – Present: Faculty member, Biomedical Graduate Group, University of Pennsylvania  
School of Medicine – Supervising one Biomedical Engineering Graduate Group  
MDPhD student presently.

Specialty Certification: 2001 American Board of Psychiatry  
Licensure: Pennsylvania

Awards, Honors and Membership in Honorary Societies:

Edward M. Stimetz Outstanding Freshman Award, Colgate University	1983
Lawrence Organic Chemistry Award, Colgate University	1984
Honors in Neuroscience, Magna Cum Laude, Phi Beta Kappa, Colgate University	1986
NARSAD Young Investigator Award	1998
APA/Organon Excellence in Psychiatry Residency Award	1999
AAP/Bristol-Myers Squibb Fellowship in Academic Psychiatry	2000
APA/Wyeth-Ayerst M.D. Ph.D. Research Fellowship in Psychiatry	2000
ACNP/ Bristol-Myers Squibb Travel Award	2001
APA/Kempf Fund Award	2001
Member, Society for Biological Psychiatry	2002
Member, American College of Neuropsychopharmacology	2004
Exemplary Psychiatrist Award, NAMI	2008

Memberships in Professional & Scientific Societies and Other Professional Activities: (offices held.)

International: None

National:

Society for Neuroscience: 1990 - present  
American Psychiatric Association: 1999 - present  
National Alliance for the Mentally Ill: 2000 - present  
Society for Biological Psychiatry: 2003 – present  
American College of Neuropsychopharmacology: 2004 – present  
(Program Committee Member: 2008)

Local:

Board of Directors, NAMI PA, Main Line Chapter: 2007 – present

Editorial Positions:

Editorial Board, *Behavioral Neuroscience*



Academic and Institutional Committees:

Experimental Therapeutics Theme Group of SOM Research Coordinating Council, 2003  
TRL Animal Users Group Committee

Major Academic and Clinical Teaching Responsibilities:

1. Director, Clinical Neurosciences Track (CNST). Course Director for weekly seminar, summer research and mentoring program for MS 1 – 4 students in CNST, 11/2007 - present
2. Brain and Behavior, MD200B - Psychopharmacology for first year medical students, 2001 - present
3. Antipsychotic pharmacology to PGY 1/2 residents, 2001 - present
4. Antipsychotic pharmacology to PGY 3/4 residents, 2001 - present
5. Schizophrenia lecture in Nursing School: 2001 – 2005
6. Independent Study Faculty Supervisor for 4 undergraduate students in BBB program and 2 students in Engineering as well as one student in Biotechnology Masters Program: 2001 – 2007
7. Senior Design, School of Engineering – Team of three to nine students per year perform design project in my laboratory every year – approximately 1 hr of lecture and 1 hr of supervision per week, 2003 – 2008
8. Animal models – lecture for Pharmacology graduate group, 9/28/06
9. Antipsychotic Medications- lecture for Medical Pharmacology Graduate course PHARMACOLOGY 600: 11/2/06
10. Clinical Supervision for 2 Residents in Psychiatry, 1 each in 2005, 2007 and 2008, 1 hr per week

Lectures by Invitation:

- 8/6/2003 The use of surgically implantable antipsychotic delivery systems for schizophrenia & Mouse models of schizophrenia using auditory evoked potentials – University of Tasmania, Hobart, Tasmania, Australia,
- 5/17/2005 Implantable Antipsychotic Medication: The rocky road from necessity to reality, University of Cincinnati, Cincinnati, OH, Grand Rounds
- 3/16/2006 Nicotine receptor subtype contributions to the beneficial and detrimental effects of nicotine on ERPs, National TTURC grantee conference, Washington, DC
- 7/19/2006 Animal models of Schizophrenia, University of Tasmania, Hobart, Tasmania Australia
- 1/9/2007 Nanotechnology and Other Novel Delivery Methods Invited lecture at NIH sponsored conference “Translational Medication Development For Nicotine Dependence Workshop”, January 8-10, 2007, Washington, DC
- 4/13/2007 From Mouse to Man by Way of the Auditory Pathway: The effects of ketamine and nicotine on auditory processing models of schizophrenia, Yale University, New Haven CT
- 4/23/2007 Event Related brain activity in mice and the alpha 7 nicotine receptor, University of Pittsburgh Medical Center, Pittsburgh, PA
- 5/16/2007 Using Event Related brain activity in mice to guide medication development: Is there a role for the alpha 7 nicotine receptor?, University of California at San Diego, San Diego, CA

- 8/28/2007 Electrophysiological Mouse Models of Schizophrenia and Semiannual Antipsychotic Drug Delivery: Balancing Mechanistic Discovery and Real World Action, Aachen, Germany
- 9/1/2007 PDE inhibitors for treatment of schizophrenia: Invited talk at the European Behavioral Pharmacology Society meeting in Tuebingen, Germany
- 11/13/2008 – Improving medication adherence in schizophrenia – University of Maryland Medical Center

#### Organizing Roles in Scientific Meetings:

1. Chair – Symposium “New approaches to improve long-term treatment adherence in Schizophrenia”, APA meeting, Chicago, IL, 5/15/2000.
2. Organizer - Symposium on Ethical Issues Regarding Surgically Implantable Medications in Psychiatry, Univ. of Pennsylvania, Philadelphia, Pennsylvania, 12/18/2003
3. INA-WFSBP Congress, Animal models of schizophrenia: A critical assessment of phenotype validation (Session Chair), Athens, Greece – 10/18/2004

#### Bibliography

##### Research Publications, peer reviewed (print or other media):

#### **During Graduate Training**

1. Siegel, S.J., S.D. Ginsberg, P.R. Hof, S.L. Foote, W.G. Young, G.W. Kraemer, W.T. McKinney, and J.H. Morrison, *Effects of social deprivation in prepubescent rhesus monkeys: immunohistochemical analysis of the neurofilament protein triplet in the hippocampal formation*. Brain Res, 1993. **619**(1-2): p. 299-305.
2. Siegel, S.J., N. Brose, W.G. Janssen, G.P. Gasic, R. Jahn, S.F. Heinemann, and J.H. Morrison, *Regional, cellular, and ultrastructural distribution of N-methyl-D-aspartate receptor subunit 1 in monkey hippocampus*. Proc Natl Acad Sci U S A, 1994. **91**(2): p. 564-8.
3. Siegel, S.J., W.G. Janssen, J.W. Tullai, S.W. Rogers, T. Moran, S.F. Heinemann, and J.H. Morrison, *Distribution of the excitatory amino acid receptor subunits GluR2(4) in monkey hippocampus and colocalization with subunits GluR5-7 and NMDAR1*. J Neurosci, 1995. **15**(4): p. 2707-19.
4. Gazzaley, A.H., S.J. Siegel, J.H. Kordower, E.J. Mufson, and J.H. Morrison, *Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys*. Proc Natl Acad Sci U S A, 1996. **93**(7): p. 3121-5.

#### **Fellowship at Penn**

5. Gur, R.C., J.D. Ragland, P.J. Moberg, W.B. Bilker, C. Kohler, S.J. Siegel, and R.E. Gur, *Computerized neurocognitive scanning: II. The profile of schizophrenia*. Neuropsychopharmacology, 2001. **25**(5): p. 777-88.
6. Gur, R.C., J.D. Ragland, P.J. Moberg, T.H. Turner, W.B. Bilker, C. Kohler, S.J. Siegel, and R.E. Gur, *Computerized neurocognitive scanning: I. Methodology and validation in healthy people*. Neuropsychopharmacology, 2001. **25**(5): p. 766-76.

**Since joining the faculty as an independent investigator in 2001**

7. Siegel, S.J., K.I. Winey, R.E. Gur, R.H. Lenox, W.B. Bilker, D. Ikeda, N. Gandhi, and W.X. Zhang, *Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia*. Neuropsychopharmacology, 2002. **26**(6): p. 817-23.
8. Bilker, W.B., C. Brensinger, M.M. Kurtz, C. Kohler, R.C. Gur, S.J. Siegel, and R.E. Gur, *Development of an abbreviated schizophrenia quality of life scale using a new method*. Neuropsychopharmacology, 2003. **28**(4): p. 773-7.
9. Connolly, P.M., C.R. Maxwell, S.J. Kanes, T. Abel, Y. Liang, J. Tokarczyk, W.B. Bilker, B.I. Turetsky, R.E. Gur, and S.J. Siegel, *Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains*. Brain Res, 2003. **992**(1): p. 85-95.
10. Gur, R.E., C. Kohler, J.D. Ragland, S.J. Siegel, W.B. Bilker, J. Loughhead, N. Phend, and R.C. Gur, *Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia*. Neuropsychopharmacology, 2003. **28**(11): p. 2029-36.
11. Kohler, C.G., T.H. Turner, W.B. Bilker, C.M. Brensinger, S.J. Siegel, S.J. Kanes, R.E. Gur, and R.C. Gur, *Facial emotion recognition in schizophrenia: intensity effects and error pattern*. Am J Psychiatry, 2003. **160**(10): p. 1768-74.
12. Moberg, P.J., S.E. Arnold, R.L. Doty, C. Kohler, S. Kanes, S. Siegel, R.E. Gur, and B.I. Turetsky, *Impairment of odor hedonics in men with schizophrenia*. Am J Psychiatry, 2003. **160**(10): p. 1784-9.
13. Ragland, J.D., S.T. Moelter, C. McGrath, S.K. Hill, R.E. Gur, W.B. Bilker, S.J. Siegel, and R.C. Gur, *Levels-of-processing effect on word recognition in schizophrenia*. Biol Psychiatry, 2003. **54**(11): p. 1154-61.
14. Siegel, S.J., P. Connolly, Y. Liang, R.H. Lenox, R.E. Gur, W.B. Bilker, S.J. Kanes, and B.I. Turetsky, *Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice*. Neuropsychopharmacology, 2003. **28**(4): p. 675-82.
15. Connolly, P.M., C. Maxwell, Y. Liang, J.B. Kahn, S.J. Kanes, T. Abel, R.E. Gur, B.I. Turetsky, and S.J. Siegel, *The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components*. Neurochem Res, 2004. **29**(6): p. 1179-88.
16. Gelber, E.I., C.G. Kohler, W.B. Bilker, R.C. Gur, C. Brensinger, S.J. Siegel, and R.E. Gur, *Symptom and demographic profiles in first-episode schizophrenia*. Schizophr Res, 2004. **67**(2-3): p. 185-94.
17. Gould, T.J., S.P. Bizily, J. Tokarczyk, M.P. Kelly, S.J. Siegel, S.J. Kanes, and T. Abel, *Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha*. Neuropsychopharmacology, 2004. **29**(3): p. 494-501.
18. Gur, R.E., C. Kohler, B.I. Turetsky, S.J. Siegel, S.J. Kanes, W.B. Bilker, A.R. Brennan, and R.C. Gur, *A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia*. Biol Psychiatry, 2004. **55**(5): p. 512-7.
19. Irani, F., M. Dankert, C. Brensinger, W.B. Bilker, S.R. Nair, C.G. Kohler, S.J. Kanes, B.I. Turetsky, P.J. Moberg, J.D. Ragland, R.C. Gur, R.E. Gur, and S.J. Siegel, *Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine*. Neuropsychopharmacology, 2004. **29**(5): p. 960-8.
20. Maxwell, C.R., Y. Liang, B.D. Weightman, S.J. Kanes, T. Abel, R.E. Gur, B.I. Turetsky, W.B. Bilker, R.H. Lenox, and S.J. Siegel, *Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential*. Neuropsychopharmacology, 2004. **29**(4): p. 739-46.

21. Maxwell, C.R., S.J. Kanes, T. Abel, and S.J. **Siegel**, *Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications*. Neuroscience, 2004. **129**(1): p. 101-7.
22. Ragland, J.D., R.C. Gur, J. Valdez, B.I. Turetsky, M. Elliott, C. Kohler, S. **Siegel**, S. Kanes, and R.E. Gur, *Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia*. Am J Psychiatry, 2004. **161**(6): p. 1004-15.
23. Talbot, K., W.L. Eidem, C.L. Tinsley, M.A. Benson, E.W. Thompson, R.J. Smith, C.G. Hahn, S.J. **Siegel**, J.Q. Trojanowski, R.E. Gur, D.J. Blake, and S.E. Arnold, *Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia*. J Clin Invest, 2004. **113**(9): p. 1353-63.
24. Budhian, A., S.J. **Siegel**, and K.I. Winey, *Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol*. J Microencapsul, 2005. **22**(7): p. 773-85.
25. Davis, J.A., J.R. James, S.J. **Siegel**, and T.J. Gould, *Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice*. J Neurosci, 2005. **25**(38): p. 8708-13.
26. Frankel, W.N., B. Beyer, C.R. Maxwell, S. Pretel, V.A. Letts, and S.J. **Siegel**, *Development of a new genetic model for absence epilepsy: spike-wave seizures in C3H/He and backcross mice*. J Neurosci, 2005. **25**(13): p. 3452-8.
27. Hans, M., K. Shimoni, D. Danino, S.J. **Siegel**, and A. Lowman, *Synthesis and characterization of mPEG-PLA prodrug micelles*. Biomacromolecules, 2005. **6**(5): p. 2708-17.
28. Maxwell, C.R., R.S. Ehrlichman, Y. Liang, D.R. Gettes, D.L. Evans, S.J. Kanes, T. Abel, J. Karp, and S.J. **Siegel**, *Corticosterone Modulates Auditory Gating in Mouse*. Neuropsychopharmacology, 2005.
29. Ragland, J.D., R.C. Gur, J.N. Valdez, J. Loughhead, M. Elliott, C. Kohler, S. Kanes, S.J. **Siegel**, S.T. Moelter, and R.E. Gur, *Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition*. Am J Psychiatry, 2005. **162**(10): p. 1840-8.
30. **Siegel**, S.J., C.R. Maxwell, S. Majumdar, D.F. Trief, C. Lerman, R.E. Gur, S.J. Kanes, and Y. Liang, *Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials*. Neuroscience, 2005. **133**(3): p. 729-38.
31. Gur, R.E., C.G. Kohler, J.D. Ragland, S.J. **Siegel**, K. Lesko, W.B. Bilker, and R.C. Gur, *Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures*. Schizophr Bull, 2006. **32**(2): p. 279-87.
32. Maxwell, C.R., R.S. Ehrlichman, Y. Liang, D. Trief, S.J. Kanes, J. Karp, and S.J. **Siegel**, *Ketamine produces lasting disruptions in encoding of sensory stimuli*. J Pharmacol Exp Ther, 2006. **316**(1): p. 315-24.
33. **Siegel**, S.J., F. Irani, C.M. Brensinger, C.G. Kohler, W.B. Bilker, J.D. Ragland, S.J. Kanes, R.C. Gur, and R.E. Gur, *Prognostic variables at intake and long-term level of function in schizophrenia*. Am J Psychiatry, 2006. **163**(3): p. 433-41.
34. Roalf, D.R., B.I. Turetsky, K. Owzar, C.C. Balderston, C.M. Brensinger, R.E. Gur, S. **Siegel**, and P.J. Moberg, *Unirhinal Olfactory Deficits in Patients with Schizophrenia and First-Degree Relatives*. Journal of Neuropsychiatry and Clinical Neurosciences, 2006. **18**: p. 389-396.

35. Hahn, C.G., H.Y. Wang, D.S. Cho, K. Talbot, R.E. Gur, W.H. Berrettini, K. Bakshi, J. Kamins, K.E. Borgmann-Winter, S.J. Siegel, R.J. Gallop, and S.E. Arnold, *Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia*. Nat Med, 2006. **12**(7): p. 824-8.
36. Maxwell, C.R., Y. Liang, M.P. Kelly, S.J. Kanes, T. Abel, and S.J. Siegel, *Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients*. Neuroscience, 2006. **141**(3): p. 1257-64.
37. Moberg, P.J., S.E. Arnold, R.L. Doty, R.E. Gur, C.C. Balderston, D.R. Roalf, R.C. Gur, C.G. Kohler, S.J. Kanes, S.J. Siegel, and B.I. Turetsky, *Olfactory functioning in schizophrenia: relationship to clinical, neuropsychological, and volumetric MRI measures*. J Clin Exp Neuropsychol, 2006. **28**(8): p. 1444-61.
38. Siegel, S.J., J.B. Kahn, K. Metzger, K.I. Winey, K. Werner, and N. Dan, *Effect of drug type on the degradation rate of PLGA matrices*. Eur J Pharm Biopharm, 2006. **64**(3): p. 287-93.
39. Irani, F., S.M. Platek, I.S. Panyavin, M.E. Calkins, C. Kohler, S.J. Siegel, M. Schachter, R.E. Gur, and R.C. Gur, *Self-face recognition and theory of mind in patients with schizophrenia and first-degree relatives*. Schizophr Res, 2006. **88**(1-3): p. 151-60.
40. Metzger, K.L., C.R. Maxwell, Y. Liang, and S.J. Siegel, *Effects of nicotine vary across two auditory evoked potentials in the mouse*. Biol Psychiatry, 2007. **61**(1): p. 23-30.
41. Phillips, J.M., R.S. Ehrlichman, and S.J. Siegel, *Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma*. Neuroscience, 2007. **144**(4): p. 1314-23.
42. Kanes, S.J., J. Tokarczyk, S.J. Siegel, W. Bilker, T. Abel, and M.P. Kelly, *Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity*. Neuroscience, 2007. **144**(1): p. 239-46.
43. Kelly, M.P., C. Isiegas, Y.F. Cheung, J. Tokarczyk, X. Yang, M.F. Esposito, D.A. Rapoport, S.A. Fabian, S.J. Siegel, G. Wand, M.D. Houslay, S.J. Kanes, and T. Abel, *Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP*. Neuropsychopharmacology, 2007. **32**(3): p. 577-88.
44. Gur, R.E., B.I. Turetsky, J. Loughhead, W. Snyder, C. Kohler, M. Elliott, R. Pratiwadi, J.D. Ragland, W.B. Bilker, S.J. Siegel, S.J. Kanes, S.E. Arnold, and R.C. Gur, *Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging*. Am J Psychiatry, 2007. **164**(3): p. 442-9.
45. Metzger, K.L., J.M. Shoemaker, J.B. Kahn, C.R. Maxwell, Y. Liang, J. Tokarczyk, S.J. Kanes, M. Hans, A.M. Lowman, N. Dan, K.I. Winey, N.R. Swerdlow, and S.J. Siegel, *Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits*. Psychopharmacology (Berl), 2007. **190**(2): p. 201-11.
46. Budhian, A., S.J. Siegel, and K.I. Winey, *Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content*. Int J Pharm, 2007. **336**(2): p. 367-75.
47. Hans, M.L., C. Maxwell, R.S. Ehrlichman, K. Metzger, Y. Liang, S.J. Siegel, and A.M. Lowman, *Evaluation of in vitro release and in vivo efficacy of mPEG-PLA-haloperidol conjugate micelle-like structures*. J Biomed Mater Res B Appl Biomater, 2007. **83**(2): p. 422-30.
48. Siegel, S., C. O'Neill, L. Dubé, P. Kaldeway, R. Morris, D. Jackson, and T. Seebree, *A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan*. Pharm Res, 2007. **24**(10): p. 1919-26.

49. Rosenberg, R., W. Devenney, S. Siegel, and N. Dan, *Anomalous release of hydrophilic drugs from poly(epsilon-caprolactone) matrices*. Mol Pharm, 2007. 4(6): p. 943-8.
50. Budhian, A., S.J. Siegel, and K.I. Winey, *Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles*. Int J Pharm, 2008, 346 (1-2): p. 151-9
51. Rabin, C., Y. Liang, R.S. Ehrlichman, A. Budhian, K.L. Metzger, C. Majewski-Tiedeken, K.I. Winey, and S.J. Siegel, *In vitro and in vivo demonstration of risperidone implants in mice*. Schizophr Res, 2008. 98(1-3): p. 66-78.
52. Majewski-Tiedeken, C.R., C.R. Rabin, and S.J. Siegel, *Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains*. Drug Alcohol Depend, 2008. 92(1-3): p. 217-27.
53. Ehrlichman, R.S., C.R. Maxwell, S. Majumdar and S.J. Siegel, *Deviance-elicited Changes in Event-related Potentials are Attenuated by Ketamine in Mice*. J Cogn Neurosci, 2008. 20(8): p. 1403-14.
54. Kelly, M.P., Y.F. Cheung, C. Favilla, S.J. Siegel, M.D. Houslay, S.J. Kanes, and T. Abel, *Constitutive activation of the G-protein subunit Gas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression*. Learning and Memory, 2008. 15: p. 75-83.
55. Dankert, M.E., C.M. Brensinger, K.L. Metzger, C. Li, S.G. Koleva, A. Mesen, B. Laprade, T. Wiguna, C. Han, S. Farooq, W.E. Severus, J.G. Gayares, J.M. Langosch, X. Lallart, M. Tateno, A. Mihai, S.R. Nair, R. Belmaker, J. Rybakowski, B. Owe-Larsson, J.M. Kane, E.C. Johnstone, D.J. Macintyre, S. Malhotra, A. Gonzalez-Pinto, F. Mosquera, S.M. Babb, E.H. Pour, S.S. Fatemi, C. Swanson, C. Adler, A. Young, F. Hoeft, K. Sivakumar, P.D. Radoeva, E.A. Lallart, W.B. Bilker, and S.J. Siegel, *Attitudes of patients and family members towards implantable psychiatric medication*. Schizophr Res, 2008.
56. Halene, T.B. and S.J. Siegel, *Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle*. J Pharmacol Exp Ther, 2008. 326(1): p. 230-9.
57. Schnoll, R.A., E.P. Wileyto, A. Pinto, Leone, F., P. Gariti, S. Siegel, K.A. Perkins, C. Dackis, D.F. Heitjan, W. Berrettini and L. C., *A placebo-controlled trial of modafinil for nicotine dependence*. Drug and Alcohol Dependence, in press.
58. Turetsky, B.I., W.B. Bilker, S.J. Siegel, C.G. Kohler and R.E. Gur, *The profile of auditory information processing deficits in schizophrenia*. Psychiatry Research, in press.
59. Amann, L.C., J.M. Phillips, T.B. Halene and S.J. Siegel, *Male and Female Mice Differ for Baseline and Nicotine-induced Event Related Potentials*. Behavioral Neuroscience, 2008. in press.
60. Ehrlichman RS, Maxwell CR, J. GM, T. LM, H FL, Contreras D, T. TB and Siegel SJ (in press) N-Methyl-D-Aspartic Acid Receptor Antagonist-Induced Frequency Oscillations In Mice Recreates Pattern Of Electrophysiological Deficits In Schizophrenia. *Neuroscience* 20.
61. Gandal, M. J., Ehrlichman, R., Rudnick, N. D., & Siegel, S. J. (in press). A Novel Electrophysiological Model of Chemotherapy-Induced Cognitive Impairments in Mice. *Neuroscience*.
62. Phillips, J. M., Maxwell, C. R., Ehrlichman, R. S., & Siegel, S. J. (in press). Event related potentials (ERPs) in the study of schizophrenia: How pre-clinical ERP studies have contributed to our understanding of schizophrenia. In D. Javitt (Ed.), *Handbook of*

*Neurochemistry and Molecular Neurobiology*, 3rd edition (Vol. 27). New York: Springer Publishers.

63. Rudnick, N. D., Koehler, C., Picciotto, M., & Siegel, S. J. (in press). Role of Beta 2-containing nicotinic acetylcholine receptors in auditory event-related potentials. *Psychopharmacology*.

#### Research Publications, peer-reviewed reviews

1. Morrison, J.H., S.J. Siegel, A.H. Gazzaley, and G.W. Huntley, *Glutamate receptors: Emerging links between subunit proteins and specific excitatory circuits in primate hippocampus and neocortex*. The Neuroscientist, 1996. 2: p. 272-283.
2. Irani, F., M. Dankert, and S.J. Siegel, *Patient and family attitudes towards schizophrenia treatment*. Current Psychiatry Reports, 2004. 6(4): p. 283-8.
3. Siegel, S.J., *Extended Release Drug Delivery Strategies in Psychiatry: Theory to Practice*. Psychiatry 2005, 2005. 2(6): p. 22-31.
4. Halene, T. and S. Siegel, *PDE Inhibitors in Psychiatry – Future Options for Dementia, Depression and Schizophrenia?* Drug Discovery Today, 2007. 12(19-20): p.870-8.
5. Lerman, C., M.G. LeSage, K.A. Perkins, S.S. O'Malley, S.J. Siegel, N.L. Benowitz, and W.A. Corrigall, *Opportunities for Translational Research in Medication Development for Drug Dependence*. Nature Reviews: Drug Discovery, 2007. 6(9): p. 746-62.
6. Phillips, J.M., S.J. Siegel, A. Shields, F. Patterson, T.J. Gould, A. Strasser, A. Pinto, M. Rukstalis, K.A. Perkins, W. Berrettini, J. Blendy, and C. Lerman, *Translating Basic Science to Improve Pharmacotherapy for Nicotine Dependence*. Nicotine and Tobacco Research. in press.

#### Contributions to peer-reviewed clinical research publications, participation cited but not by authorship:

None

#### Research Publications, non-peer reviewed: None

#### Abstracts: (Please list only those in the past 3 years.)

1. Siegel, S. J., Shoemaker, J. M., Swerdlow, N. R., Beckerman, W., Liang, Y., Tokarczyk, J., Kanes, S. J., Abel, T., Maxwell, C. R., Surgically Implantable Long - term Delivery Systems for Atypical Antipsychotic Medications, ACNP meeting, 12/13/2004, San Juan, PR
2. Kelly; M., Tokarczyk; J., Rapoport, D.A.' Siegel, S. J., Kanes; S., Abel, T., Haloperidol Ameliorates the Reductions in Sensorimotor Gating and Camp Levels Seen in Mice Over expressing the G - Protein Subunit G AlphaS, ACNP meeting, 12/13/2004, San Juan, PR
3. Feifel, D., Siegel, S., Melendez, G., Shilling, P.D., Surgically Implantable Long - Term Antipsychotic Delivery System Produces Progressive Reversal of PPI Deficits in Brattleboro Rats, ACNP meeting, 12/14/2004, San Juan, PR
4. Kohler, C.G., Bilker, W., Siegel, S.J., Kanes, S.J., Gur, R.E., 1 - 2 Year Outcome Associated with Naturalistic Treatment in First Episode Schizophrenia, ACNP meeting, 12/14/2004, San Juan, PR
5. Maxwell, C.R., Liang, Y., Kelly, M. P., Kanes, S. J. Abel, T., Siegel, S.J., Transgenic Mice Expressing Constitutively Active Gsa Exhibit Sensory Encoding Deficits, Talk in

- symposium "Animal models of Schizophrenia, S. J. Siegel, Session Chair, Soc. Neurosci. 11/13/2005., Washington, DC
6. Siegel, S. J., Ehrlichman, R. S., Maxwell, C., Majumdar, S., Frequency Mismatch Negativity in Mice is Attenuated by Ketamine, ACNP meeting, 12/16/2005, Waikalua, HI
  7. Kelly, M., Esposito, M., Tokarczyk, J., Siegel, S. J., Kanes, S., Abel, T., Constitutive Activation of the G - Protein Subunit Gas Causes Behavioral and Biochemical Deficits Due to a PKA - Dependent Upregulation of PDE Activity, ACNP meeting, 12/17/2005, Waikalua, HI
  8. Effects Of Nicotine Vary Across Two Auditory Evoked Potentials In The Mouse, SRNT, 3/17/2006, Orlando, FL
  9. Siegel, S.J., Ehrlichman, R.S. Phillips, J.M., Liang, Y., Turetsky, B.I. Aillon, D., Johnson, D., Ketamine Causes Persistent Evoked Gamma Oscillations Similar To Schizophrenia And Reduced Hippocampal Glutamate Concentrations In Mice, Soc Biol Psych. 5/20/2006, Toronto, Canada
  10. Siegel, S.J., Majewski-Tiedeken, C., Rabin, C., Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains Soc. Neurosci. 11/17/2006, Atlanta, GA
  11. Siegel, S.J. Phillips, J.M., Ehrlichman, R.S., Alpha 4 Beta 2 but not Alpha 7 Nicotine receptor subtypes contribute to augmentation of mouse correlate of human P50, ACNP, 12/5/2006 – Hollywood FL
  12. Phillips, J.M., Ehrlichman, R.S., Siegel, S.J. Differential effects of chronic nicotine on event related potential components and evoked gamma, SRNT, 2/22/2007, Austin TX.
  13. Ehrlichman, R.S., Maxwell, C.R., Turetsky, B.I., Siegel, S.J., .N-methyl-D-aspartic acid receptor antagonist induced frequency oscillations in mice recreates pattern of for electrophysiological deficits in schizophrenia, Platform Presentation, Soc. Neurosci. 11/5/2007, San Diego, CA
  14. Rabin, C., Liang, Y., Ehrlichman, R.S., Budhian, A., Metzger, K., Majewski-Tiedeken, C., Winey, K., Siegel, S.J., In vitro and in vivo demonstration of risperidone implants in mice, Platform Presentation, Soc. Neurosci. 11/5/2007, San Diego, CA
  15. Halene, T.B., Ehrlichman, R.S., Liang, Y., Christian, E.P., Jonak, G.J., Gur, T.L., Blendy, J.A., Dow, H.C., Brodtkin, E.S., Schneider, F., Gur, R.C., Siegel, S.J., Electrophysiological and behavioral characteristics of reduced N-methyl-D-aspartate receptor expression in mice and its relevance for schizophrenia, .Platform Presentation, Soc. Neurosci. 11/5/2007, San Diego, CA
  16. Majewski-Tiedeken, C.R., Rabin, C.R., Siegel, S.J., Ketamine exposure in adult mice causes quantifiable apoptotic and necrotic cell death in CA3 Hippocampus of C3H, DBA2 and FVB inbred mouse strains, Platform Presentation, Soc. Neurosci. 11/5/2007, San Diego, CA
  17. Amann, L.C., Liang, Y., Lin, R., Burnbaum, J., **Siegel, S. J.** In vitro and in vivo demonstration of continuously extruded risperidone implants in rats, Platform presentation, Society for Neuroscience annual meeting, Washington DC, Nov 2008
  18. Lin, R., Liang, Y., Amann, L.C., **Siegel, S. J.**, Adaptive changes in binding affinities for D2 and 5-HT2 receptors in striatum following chronic and intermittent risperidone in rats, Platform presentation, Society for Neuroscience annual meeting, Washington DC, Nov 2008



19. Rudnick, N.D., Koehler, C.J., Picciotto, M.R., Lerman, C., **Siegel, S. J.**; Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials, Platform presentation, Society for Neuroscience annual meeting, Washington DC, Nov 2008
20. Liang, Y., Lin, R., Amann, L.C., **Siegel, S. J.**, Distribution of risperidone and 9-oh-risperidone in different regions of rat brain, Platform presentation, Society for Neuroscience annual meeting, Washington DC, Nov 2008

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. **Siegel, S.J.**, *Increased patient autonomy through long-term antipsychotic delivery systems in schizophrenia*. Exert Rev. Neurotherapeutics, 2002. **2**(6): p. 89-91.
2. Hans, M.L., L. Dan, K.I. Winey, A.M. Lowman, and S.J. **Siegel**, *Daily to Annual Biodegradable Drug Delivery Strategies for Psychoactive Compounds*, in *Handbook of Biodegradable Polymeric Materials & Applications*, S.K. Mallapragada, Editor. 2004, American Scientific Publishers: Stevenson Ranch, CA.
3. **Siegel, S.J.**, *Extended-Release Intramuscular Naltrexone*. Drugs, 2006. **66**(13): p. 1752.
4. Kane, J.M., S. Leucht, S.R. Marder, D.G. Robinson, and S.J. **Siegel**, *New Developments in the Treatment of Schizophrenia*. J Clin Psychiatry, 2007. **68**.
5. **Siegel, S.J.**, M. Dankert, and J.M. Phillips, *Psychosis and Schizophrenia (chapter 55)*, in *Pharmacology and Therapeutics: Principles to Practice* S. Waldman and A. Terzic, Editors., in press Elsevier: Philadelphia.
6. Phillips, J.M., C.R. Maxwell, R.S. Ehrlichman, and S.J. **Siegel**, *Event related potentials (ERPs) in the study of schizophrenia: How pre-clinical ERP studies have contributed to our understanding of schizophrenia*, in *Handbook of Neurochemistry and Molecular Neurobiology, 3rd edition*, D. Javitt, Editor. in press, Springer Publishers: New York.

Books: None

Alternative Media: None

A service of the [U.S. National Library of Medicine](#)  
and the [National Institutes of Health](#)**My NCBI** [?] [\[Sign In\]](#) [\[Register\]](#)All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals  
Search PubMed for Boisdron Celle 1995 fluorouracil   [Advanced Search](#)  
[Save Search](#)[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

Display AbstractPlus Show 20 Sort By Send to

All: 1 Review: 0

☐ 1: J Pharm Pharmacol. 1995 Feb;47(2):108-14.[Links](#)**Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers.****Boisdron-Celle M, Menei P, Benoit JP.**

Laboratoire de Pharmacie Galénique et Biophysique Pharmaceutique, Faculté de Pharmacie, Angers, France.

To provide a device releasing 5-fluorouracil in a controlled manner and injectable into the brain by stereotaxy, biodegradable poly ((+/-)-lactide-co-glycolide) (PLGA) microparticles were prepared by an emulsion-extraction process. Although the solubility profile of the drug was not suitable for its encapsulation by the aforementioned method, careful choice of process variables allowed significant drug loading, reaching 30%. Thus, the size of the 5-fluorouracil crystals, the organic phase/aqueous phase ratio, the theoretical drug loading and the microparticle size played a predominant role. The microsphere size was adjusted to 20-40 microns by selecting the appropriate PLGA and polyvinylalcohol concentrations, and the stirring rate of the initial emulsion. It was shown that the microparticle structure depended directly on the experimental conditions governing the precipitation rate of the coating material: two types of microparticles, I and II, were characterized. The morphology of the particles influenced the 5-fluorouracil-release patterns, as did other process parameters, such as the 5-fluorouracil crystal size and the PLGA concentration. It was possible to sustain the 5-fluorouracil release over 18 days.

PMID: 7602463 [PubMed - indexed for MEDLINE]

**Related Articles**

Effect of WOW process parameters on morphology and burst release of FITC-dextran loader [Int J Pharm. 2007]

5-Fluorouracil-loaded chitosan coated poly(lactic acid) microspheres as biodegradable [J Microencapsul. 2000]

Formulation factors for preparing ocular biodegradable delivery system of 5-fluorouracil [J Microencapsul. 2001]

Review Nano/micro technologies for delivering macromolecular therapeutics [J Control Release. 2008]

Review The manufacturing techniques of various drug loaded biodegradable poly(lactide- [Biomaterials. 2000]

[» See Reviews...](#) | [» See All...](#)**Patient Drug Information**

Fluorouracil (Acrucil®) Your doctor has ordered the drug fluorouracil to help treat your illness. The drug is given by injection into a vein.

[» read more ...](#)**Recent Activity**[Turn Off](#) [Clear](#)

Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable ...

[Boisdron Celle 1995 fluor... \(1\)](#) [PubMed](#)

Dissimilar effects in acute toxicity studies of CDP-choline and choline.

CDP-choline: acute toxicity study.

Citicoline: pharmacological and clinical review, 2006 update.

Display AbstractPlus Show 20 Sort By Send to

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health &amp; Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)